Health TrialsbyHealthPanel

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Safety and Activity of HF50 in Patients With Advanced Solid Tumors

A study to assess the safety, tolerability, and pharmacokinetics of HF50 in participants with advanced solid tumors.

Participants needed: 45
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: HighField Biopharmaceuticals CorporationUpdated: Sep 28, 2026Locations: 2
Eligibility criteria

Voluntary participation: Capable of giving signed informed consent and able to c... [+6]

Autoimmune Disease: Any active autoimmune disease or history of autoimmune disea... [+10]

Read more
Status: Recruiting

A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma

The primary purpose of this Phase II study is to evaluate the preliminary anti-tumor efficacy of HF1K16 in combination with Bevacizumab in patients with recurrent or progressive glioma. The study also evaluates the safety and tolerability of the combination therapy.

Participants needed: 30
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: HighField Biopharmaceuticals CorporationUpdated: Jul 10, 2026Locations: 1
Eligibility criteria

The patient and/or guardian must voluntarily sign and date a written informed co... [+11]

Any active autoimmune disease, or a history of autoimmune disease requiring syst... [+11]

Read more
Status: Recruiting

HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors

HF158K1 is an investigational liposome form of doxorubicin hydrochloride, an anthracycline topoisomerase inhibitor, encapsulated by lipid membranes containing TL01, a HER2-directed Trastuzumab Fab fragment conjugated lipid.

Participants needed: 84
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: HighField Biopharmaceuticals CorporationUpdated: Jun 26, 2026Locations: 2
Eligibility criteria

Voluntary to participate and sign ICF. [+7]

Cumulative doxorubicin dose ≥ 350 mg/m² or prior anthracycline-induced cardiotox... [+8]

Read more
Status: Recruiting

HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors

This is an open-label, single-arm, non-randomized, single-center, dose-escalation study designed to evaluate the safety and tolerability of HF50 in patients with HER-2 positive and HER-2 low-expression advanced solid tumors. The primary objectives are to assess the safety, tolerability, and determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of HF50. Secondary objectives include evaluating the pharmacokinetic (PK) profile and preliminary antitumor activity of HF50.

Participants needed: 10
Trial details
Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: HighField Biopharmaceuticals CorporationUpdated: Aug 17, 2025Locations: 1
Eligibility criteria

Participants must voluntarily provide written informed consent (ICF) prior to an... [+7]

History of active autoimmune disease or autoimmune disease considered unsuitable... [+10]

Read more